Cancer Stem Cells Are Enriched in the Side Population Cells in a Mouse Model of Glioma

Overview

Journal Cancer Res

Specialty Oncology

Date 2008 Dec 17

PMID 19074870

Citations 82

Authors

Molly A Harris

Hyuna Yang

Benjamin E Low

Joydeep Mukherjee

Joydeep Mukherje

Abhijit Guha

Roderick T Bronson

Leonard D Shultz

Mark A Israel

Kyuson Yun

Affiliations

Soon will be listed here.

Abstract

The recent identification of cancer stem cells (CSCs) in multiple human cancers provides a new inroad to understanding tumorigenesis at the cellular level. CSCs are defined by their characteristics of self-renewal, multipotentiality, and tumor initiation upon transplantation. By testing for these defining characteristics, we provide evidence for the existence of CSCs in a transgenic mouse model of glioma, S100beta-verbB;Trp53. In this glioma model, CSCs are enriched in the side population (SP) cells. These SP cells have enhanced tumor-initiating capacity, self-renewal, and multipotentiality compared with non-SP cells from the same tumors. Furthermore, gene expression analysis comparing fluorescence-activated cell sorting-sorted cancer SP cells to non-SP cancer cells and normal neural SP cells identified 45 candidate genes that are differentially expressed in glioma stem cells. We validated the expression of two genes from this list (S100a4 and S100a6) in primary mouse gliomas and human glioma samples. Analyses of xenografted human glioblastoma multiforme cell lines and primary human glioma tissues show that S100A4 and S100A6 are expressed in a small subset of cancer cells and that their abundance is positively correlated to tumor grade. In conclusion, this study shows that CSCs exist in a mouse glioma model, suggesting that this model can be used to study the molecular and cellular characteristics of CSCs in vivo and to further test the CSC hypothesis.

Citing Articles

Therapeutic approaches to modulate the immune microenvironment in gliomas.

Sarantopoulos A, Ene C, Aquilanti E NPJ Precis Oncol. 2024; 8(1):241.

PMID: 39443641 PMC: 11500177. DOI: 10.1038/s41698-024-00717-4.

Human esophageal cancer stem-like cells escape the cytotoxicity of natural killer cells via down-regulation of ULBP-1.

Tang B, Guo M, Zhai Y, Zhang K, Ni K, Zhang Y J Transl Med. 2024; 22(1):737.

PMID: 39103915 PMC: 11301968. DOI: 10.1186/s12967-024-05549-1.

KR158 Spheres Harboring Slow-Cycling Cells Recapitulate High-Grade Glioma Features in an Immunocompetent System.

Chakraborty A, Yang C, Kresak J, Silver A, Feier D, Tian G Cells. 2024; 13(11.

PMID: 38891070 PMC: 11171638. DOI: 10.3390/cells13110938.

S100A6: molecular function and biomarker role.

Wang Y, Kang X, Kang X, Yang F Biomark Res. 2023; 11(1):78.

PMID: 37670392 PMC: 10481514. DOI: 10.1186/s40364-023-00515-3.

Distinct Lineage of Slow-Cycling Cells Amidst the Prevailing Heterogeneity in Glioblastoma.

Mahajan S, Schmidt M Cancers (Basel). 2023; 15(15).

PMID: 37568659 PMC: 10417372. DOI: 10.3390/cancers15153843.

References

Mani S, Yang J, Brooks M, Schwaninger G, Zhou A, Miura N . Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci U S A. 2007; 104(24):10069-74. PMC: 1891217. DOI: 10.1073/pnas.0703900104. View

Dalerba P, Dylla S, Park I, Liu R, Wang X, Cho R . Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007; 104(24):10158-63. PMC: 1891215. DOI: 10.1073/pnas.0703478104. View

Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-8. PMC: 153034. DOI: 10.1073/pnas.0530291100. View

Goodell M, Brose K, Paradis G, Conner A, Mulligan R . Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996; 183(4):1797-806. PMC: 2192511. DOI: 10.1084/jem.183.4.1797. View

Siemann D, Keng P . Cell cycle specific toxicity of the Hoechst 33342 stain in untreated or irradiated murine tumor cells. Cancer Res. 1986; 46(7):3556-9. View

Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner P . CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007; 67(9):4010-5. DOI: 10.1158/0008-5472.CAN-06-4180. View

Hermann P, Huber S, Herrler T, Aicher A, Ellwart J, Guba M . Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2008; 1(3):313-23. DOI: 10.1016/j.stem.2007.06.002. View

Hemmati H, Nakano I, Lazareff J, Masterman-Smith M, Geschwind D, Bronner-Fraser M . Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A. 2003; 100(25):15178-83. PMC: 299944. DOI: 10.1073/pnas.2036535100. View

Rich J . Cancer stem cells in radiation resistance. Cancer Res. 2007; 67(19):8980-4. DOI: 10.1158/0008-5472.CAN-07-0895. View

10.

Wang J, Sakariassen P, Tsinkalovsky O, Immervoll H, Boe S, Svendsen A . CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer. 2007; 122(4):761-8. DOI: 10.1002/ijc.23130. View

11.

OBrien C, Pollett A, Gallinger S, Dick J . A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2006; 445(7123):106-10. DOI: 10.1038/nature05372. View

12.

Ma S, Lee T, Zheng B, Chan K, Guan X . CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene. 2007; 27(12):1749-58. DOI: 10.1038/sj.onc.1210811. View

13.

Ohuchida K, Mizumoto K, Yu J, Yamaguchi H, Konomi H, Nagai E . S100A6 is increased in a stepwise manner during pancreatic carcinogenesis: clinical value of expression analysis in 98 pancreatic juice samples. Cancer Epidemiol Biomarkers Prev. 2007; 16(4):649-54. DOI: 10.1158/1055-9965.EPI-06-0157. View

14.

Szotek P, Pieretti-Vanmarcke R, Masiakos P, Dinulescu D, Connolly D, Foster R . Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A. 2006; 103(30):11154-9. PMC: 1544057. DOI: 10.1073/pnas.0603672103. View

15.

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

16.

Zhang M, Behbod F, Atkinson R, Landis M, Kittrell F, Edwards D . Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res. 2008; 68(12):4674-82. PMC: 2459340. DOI: 10.1158/0008-5472.CAN-07-6353. View

17.

Hill R . Identifying cancer stem cells in solid tumors: case not proven. Cancer Res. 2006; 66(4):1891-5. DOI: 10.1158/0008-5472.CAN-05-3450. View

18.

le Viseur C, Hotfilder M, Bomken S, Wilson K, Rottgers S, Schrauder A . In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell. 2008; 14(1):47-58. PMC: 2572185. DOI: 10.1016/j.ccr.2008.05.015. View

19.

Cho R, Wang X, Diehn M, Shedden K, Chen G, Sherlock G . Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells. 2007; 26(2):364-71. DOI: 10.1634/stemcells.2007-0440. View

20.

Komatsu K, Murata K, Kameyama M, Ayaki M, Mukai M, Ishiguro S . Expression of S100A6 and S100A4 in matched samples of human colorectal mucosa, primary colorectal adenocarcinomas and liver metastases. Oncology. 2002; 63(2):192-200. DOI: 10.1159/000063812. View